Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Nadine G. D. Schirmbeck(University Hospital Bonn), Ingo G.H. Schmidt‐Wolf(University Hospital Bonn), Ulrich Mey(Kantonsspital Graubünden), Dimitri Flieger(Klinikum Aschaffenburg), Mathias Witzens‐Harig(Heidelberg University), Ulrich Kaiser(University of Applied Sciences Landshut), Yon‐Dschun Ko(Johanniter-Krankenhaus Bonn), Attilio Olivieri(Ospedali Riuniti di Ancona)

Cancer Investigation

September 13, 2016

10.1080/07357907.2016.1212062

Cited by 10

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2020|568

<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

|Journal of Clinical Oncology|2011|450

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics

|PLoS Genetics|2008|395